Ingevity Corp (NGVT) stock
Close on Nov 17, 2026Market cap $2.04BP/E 40.3Yield –
Earnings
Ingevity's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Ingevity's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 24, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026after the close | $305.10M | -15.7% | $1.46 | $1.63 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 29, 2026after the close | $314.10M | -14.0% | $1.13 | $1.74 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026after the close | $258.00M | -9.2% | $0.65 | $1.15 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026after the close | $255.10M | – | -$2.21 | $0.58 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025after the close | $362.10M | -3.9% | $1.18 | $1.52 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 4, 2025after the close | $365.10M | -6.5% | -$4.02 | $1.39 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 5, 2025after the close | $284.00M | -16.5% | $0.56 | $0.99 | Release |
| Q4 FY2024ended Dec 31, 2024 | Jan 16, 2025before the open | – | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 29, 2024after the close | $376.90M | -15.5% | -$2.95 | $1.10 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 31, 2024after the close | $390.60M | -18.9% | -$7.81 | $1.01 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 1, 2024after the close | $340.10M | -13.4% | -$1.54 | $0.52 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 21, 2024after the close | $371.70M | -3.1% | -$3.23 | $0.21 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 1, 2023after the close | $446.00M | -7.5% | $0.69 | $1.21 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 2, 2023after the close | $481.80M | +14.7% | $0.97 | $1.41 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 3, 2023after the close | $392.60M | +2.6% | $1.35 | $1.09 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 27, 2023after the close | $383.60M | +14.2% | $0.41 | $0.57 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022after the close | $482.00M | +27.9% | $1.98 | $2.09 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 2, 2022after the close | $419.90M | – | $1.54 | $1.73 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022after the close | $382.80M | – | $1.55 | $1.62 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 23, 2022after the close | $336.00M | – | $0.74 | $0.78 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 27, 2021after the close | $376.80M | – | -$0.11 | $1.62 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 28, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 28, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 10, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 20, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Ingevity's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| net salesGAAP | FY2026 | $1.10B | – | New | Nov 4, 2026 |
| net sales | FY2026 | $1.05B – $1.15B | $1.05B – $1.15B | Reaffirmed | Jul 29, 2026 |
| adjusted EBITDAnon-GAAP | FY2026 | $385.00M – $395.00M | – | New | Nov 4, 2026 |
| adjusted EBITDAnon-GAAP | FY2026 | $380.00M – $400.00M | $370.00M – $395.00M | Raised | Jul 29, 2026 |
| diluted adjusted EPSnon-GAAP | FY2026 | $5.25 – $5.45 | – | New | Nov 4, 2026 |
| diluted adjusted EPSnon-GAAP | FY2026 | $5.00 – $5.45 | $4.70 – $5.20 | Raised | Jul 29, 2026 |
| Free cash flownon-GAAP | FY2026 | $220.00M – $230.00M | – | New | Nov 4, 2026 |
| Free cash flownon-GAAP | FY2026 | $220.00M – $245.00M | $215.00M – $245.00M | Raised | Jul 29, 2026 |
Guidance vs results
The last range Ingevity gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $1.25B – $1.35B | $1.27BΣ4Q | Within range |
Guidance history
Every forecast Ingevity put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | adjusted EBITDA | FY2026 | $385.00M – $395.00M | New |
| Nov 4, 2026 | diluted adjusted EPS | FY2026 | $5.25 – $5.45 | New |
| Nov 4, 2026 | Free cash flow | FY2026 | $220.00M – $230.00M | New |
| Nov 4, 2026 | net sales | FY2026 | $1.10B | New |
| Jul 29, 2026 | adjusted EBITDA | FY2026 | $380.00M – $400.00M | Raised |
| Jul 29, 2026 | diluted adjusted EPS | FY2026 | $5.00 – $5.45 | Raised |
| Jul 29, 2026 | Free cash flow | FY2026 | $220.00M – $245.00M | Raised |
| Jul 29, 2026 | net sales | FY2026 | $1.05B – $1.15B | Reaffirmed |
| May 6, 2026 | adjusted EBITDA | FY2026 | $370.00M – $395.00M | Lowered |
| May 6, 2026 | adjusted EPS | FY2026 | $4.70 – $5.20 | Lowered |
| May 6, 2026 | Free cash flow | FY2026 | $215.00M – $245.00M | Lowered |
| May 6, 2026 | net sales | FY2026 | $1.05B – $1.15B | Lowered |
| Feb 25, 2026 | adjusted EBITDA | FY2026 | $380.00M – $400.00M | New |
| Feb 25, 2026 | adjusted EPS | FY2026 | $4.80 – $5.20 | New |
| Feb 25, 2026 | Free cash flow | FY2026 | $225.00M – $250.00M | New |
| Feb 25, 2026 | net sal es | FY2026 | $1.10B – $1.20B | New |
| Nov 5, 2025 | total adjusted EBITDA | FY2025 | $390.00M – $405.00M | New |
| Nov 5, 2025 | total net sales | FY2025 | $1.25B – $1.35B | New |
| Aug 4, 2025 | adjusted EBITDA | FY2025 | $390.00M – $415.00M | Raised |
| Aug 4, 2025 | sales | FY2025 | $1.25B – $1.40B | Reaffirmed |
| May 5, 2025 | adjusted EBITDA | FY2025 | $380.00M – $415.00M | Lowered |
| May 5, 2025 | sales | FY2025 | $1.25B – $1.40B | New |
| Jan 16, 2025 | Adjusted EBITDA | FY2025 | $400.00M | New |
| Oct 29, 2024 | adjusted EBITDA | FY2024 | $350.00M – $360.00M | Reaffirmed |
| Oct 29, 2024 | sales | FY2024 | $1.40B – $1.50B | New |
| Jul 31, 2024 | adjusted EBITDA | FY2024 | $350.00M – $360.00M | Lowered |
| Jul 31, 2024 | sales | FY2024 | $1.40B – $1.50B | Lowered |
| May 1, 2024 | adjusted EBITDA | FY2024 | $365.00M – $390.00M | Reaffirmed |
| May 1, 2024 | sales | FY2024 | $1.40B – $1.55B | Reaffirmed |
| Feb 21, 2024 | adjusted EBITDA | FY2024 | $365.00M – $390.00M | New |
| Feb 21, 2024 | sales | FY2024 | $1.40B – $1.55B | New |
| Nov 1, 2023 | adjusted EBITDA | FY2023 | $375.00M – $390.00M | Lowered |
| Aug 2, 2023 | adjusted EBITDA | FY2023 | $390.00M – $420.00M | Lowered |
| Aug 2, 2023 | sales | FY2023 | $1.60B – $1.70B | Lowered |
| May 3, 2023 | adjusted EBITDA | FY2023 | $450.00M – $480.00M | Lowered |
| May 3, 2023 | sales | FY2023 | $1.75B – $1.95B | New |
| Feb 27, 2023 | adjusted EBITDA | FY2023 | $495.00M – $515.00M | New |
| Feb 27, 2023 | sales | FY2023 | $1.90B – $2.10B | New |
| Nov 2, 2022 | adjusted EBITDA | FY2022 | $460.00M – $475.00M | Raised |
| Nov 2, 2022 | sales | FY2022 | $1.65B – $1.70B | Raised |
| Aug 2, 2022 | adjusted EBITDA | FY2022 | $430.00M – $470.00M | Reaffirmed |
| Aug 2, 2022 | sales | FY2022 | $1.53B – $1.65B | Reaffirmed |
| May 4, 2022 | adjusted EBITDA | FY2022 | $430.00M – $470.00M | Raised |
| May 4, 2022 | sales | FY2022 | $1.53B – $1.65B | Raised |
| Feb 23, 2022 | adjusted EBITDA | FY2022 | $430.00M – $460.00M | New |
| Feb 23, 2022 | sales | FY2022 | $1.53B – $1.60B | New |
| Oct 27, 2021 | adjusted EBITDA | FY2021 | $405.00M – $420.00M | New |
| Oct 27, 2021 | sales | FY2021 | $1.32B – $1.36B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Ingevity filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Results
- Results
- Update
- Update
- Update
- Update
- Results
- Update
- Update
- Results
- Update
See a number that looks wrong?